stockrow
Friday 6 November 2026
Export ACRV’s income statement to Excel — free account
Acrivon Therapeutics, Inc.
ACRV Healthcare Biotechnology
- EPS
- +21.8%
- Free cash flow
- +12.6%
Quarter to June 2026, against a year earlier
1.59
0.02
+1.27%
Follow ACRV
Alert me
Acrivon Therapeutics, Inc. (ACRV) P/E ratio
Acrivon Therapeutics, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| MNOV MediciNova, Inc. compare | n/m |
| CNXU Conexeu Sciences Inc. compare | n/m |
| RANI Rani Therapeutics Holdings, Inc. compare | n/m |
| NTRB Nutriband Inc. compare | n/m |
| NORD Nordicus Partners Corporation compare | n/m |
| ACRV Acrivon Therapeutics, Inc. | n/m |
| CSBR Champions Oncology, Inc. compare | n/m |
| COYA Coya Therapeutics, Inc. compare | n/m |
| MAIA MAIA Biotechnology, Inc. compare | n/m |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)